Interius BioTherapeutics

Interius BioTherapeutics is a biopharmaceutical company that develops in vivo cell-specific gene medicines to treat B cell lymphomas. Intravenous in vivo CAR treatment, which treats B cell lymphomas, is the company's flagship program. Its unique engineering provides exceptional target tissue specificity. The business is working on a second initiative to address autoimmune conditions. With the help of Interius, a novel and distinct therapeutic modality for the precise administration of gene therapies may soon be made available to patients in expanded care settings, without the need for preconditioning chemotherapy.

Interius BioTherapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Biopharma, Therapeutics sector. The company focuses on Biotechnology and has secured $9.9B in funding across 64 round(s). With a team of 11-50 employees, Interius BioTherapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Interius BioTherapeutics, raised $51.4M. Discover more about their projects, partnerships, and impact on our platform.